Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

NCT03233178 · Completed

Last updated 2026-05-28

This study looked at how starting certain diabetes medications (SGLT2 inhibitors, Liraglutide, or Sitagliptin) affects liver enzyme levels in adults with type 2 diabetes in real-world settings.

Status Completed The study has finished.

Type Observational

Participants 4,000 people

Who can join Ages 18+ · all sexes

Timeline Started 2017-01 · est. completion 2017-06

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT03233178 ↗

Description as written by the study sponsor.

The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or sitagliptin, compared to a control group of patients who did not initiate a new antihyperglycemic therapy. The hypothesis is that patients using Sodium Glucose Cotransporter 2 inhibitors (SGLT2i) will achieve a greater reduction in ALT compared to the control group.

Treatments tested

Non-interventional Other

Main thing measured	Change in ALT in patients with T2DM initiating SGLT2 inhibitors, Liraglutide or Sitagliptin compared to control
Sponsor	LMC Diabetes & Endocrinology Ltd.
Conditions studied	T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03233178 ↗